Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

BIOSANTE Form 4 August 12, 2	PHARMACEUT	FICALS I	NC							
FORM	1 /								OMB A	PPROVAL
FURIN	UNITED	STATES					IGE (COMMISSION	OMB Number:	3235-0287
Check the if no long			Washington, D.C. 20549						Expires:	January 31,
subject to Section 1 Form 4 o Form 5	6. r	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,								2005 average Irs per 0.5
obligation may cont <i>See</i> Instru 1(b).	ns inue. Section 17(a) of the l	Public Ut		ing Com	pany	Act of	f 1935 or Section	n	
(Print or Type I	Responses)									
1. Name and A MANGANO	ddress of Reporting D ROSS J	Person <u>*</u>	Symbol BIOSAN	Name and NTE PHA		-	-	5. Relationship of Issuer (Chec	Reporting Per k all applicable	
			INC [BF	-					**	
		Middle) C., 111	3. Date of (Month/D 08/12/20	-	insaction			XDirector Officer (give below)		6 Owner er (specify
LINCOLNS	(Street) SHIRE, IL 60069			ndment, Dat th/Day/Year)	-			6. Individual or Jo Applicable Line) _X_ Form filed by 0 Form filed by M	One Reporting Pe	erson
(City)	(State)	(Zip)	Tabl	I New D	! 6	.		Person	· Danafiaial	ller Ormend
1.Title of	2. Transaction Dat			3.				uired, Disposed of 5. Amount of	6. Ownership	•
Security (Instr. 3)	(Month/Day/Year)	Executio any	n Date, if Day/Year)		(D) (Instr. 3, 4	sposed	of	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)
Common	08/12/2011			Code V P	Amount 25,000	(D) A	Price \$		I	By Trust
Stock	00/12/2011				23,000	11	2.4	15,555	1	(1)
Common Stock								1,929,661	I	By JO & Co.
Common Stock								30,000	I	See footnote (2)
Common Stock								33,333	I	By Trust
								33,333	I	

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

Common Stock			By Trust
Common Stock	100,000	Ι	See footnote (3)
Common Stock	165,756	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Other

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	5		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
			Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer			
MANGANO ROSS J C/O BIOSANTE PHARMACEUTICALS, IN 111 BARCLAY BOULEVARD LINCOLNSHIRE, IL 60069	C.	Х					
Signatures							
/s/ Phillip B. Donenberg, attorney-in-fact	08/	/12/2011					
**Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares are held indirectly by Mr. Mangano in various trusts of which Mr. Mangano is the trustee
- (2) Shares are held by Oliver & Co., of which Mr. Mangano is a trustee.
- (3) Shares are indirectly held by Mr. Mangano as an investment advisor on behalf of an individual.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.